Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RECCE 327
- Development stage
- Phase 3
- Lead developer
- Recce Pharmaceuticals
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous, Topical
01
Overview
RECCE 327 is a synthetic broad-spectrum anti-infective and antibiotic developed by Recce Pharmaceuticals. It is designed to treat serious and potentially life-threatening infections caused by both Gram-positive and Gram-negative bacteria, including multi-drug resistant "superbug" forms such as the ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, Enterobacter species). The drug demonstrates rapid bactericidal activity, achieving 99.9% effectiveness against ESKAPE pathogens within minutes of exposure. Its mechanism of action includes irreversibly binding to essential bacterial proteins (protein inhibition) and disrupting cellular metabolism and energy production (depleting ATP). RECCE 327 kills bacteria rapidly without inducing cell lysis and maintains efficacy even with repeated use without promoting resistance. It can be administered intravenously or topically, with ongoing clinical development for various severe bacterial infections.
- Other names
- R-327R327R 327
Beyond the preview
Go deeper on RECCE 327.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RECCE 327.